News2021-05-28T14:12:08-05:00
101, 2018

Jeff Aronin Named One of the 20 Most Influential Leaders in Healthcare for 2018

Paragon CEO Jeff Aronin Recognized by Insights Care Magazine as “Innovative Entrepreneur Putting Patients First” October 1, 2018 – Paragon Biosciences CEO Jeff Aronin was recognized this week by Insights Care magazine for his innovative leadership in the biosciences sector and for his work bringing life-altering drugs to patients in need. Jeff’s vision has led [...]

0821, 2018

Paragon Biosciences Announces Skyline Biosciences as the Newest Addition to Its Growing Portfolio of Companies

CHICAGO – August 21, 2018 – Paragon Biosciences (Paragon) today announced Skyline Biosciences (Skyline) as the newest addition to its growing portfolio of drug-development companies. Paragon identifies unmet patient needs, invests in the development of novel medicines, and incubates biopharmaceutical companies, such as Skyline. “Skyline is working on promising therapies to treat oral precancerous lesions,” [...]

0814, 2018

Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome

CHICAGO – August 14, 2018 – Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in [...]

089, 2018

Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex

Biopharmaceutical company currently evaluating diacerein 1% ointment (CCP-020) in ongoing DELIVERS study PARSIPPANY, NJ – August 9, 2018 – Castle Creek Pharmaceuticals, LLC., a US-based company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. Food & Drug Administration (FDA) has designated as a [...]

0625, 2018

Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment

New multi-center Phase 1 study expected to enroll up to 20 people living with rare genetic condition that leads to extremely fragile skin PARSIPPANY, NJ – June 25, 2018 – Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that [...]

0516, 2018

Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa

PARSIPPANY, N.J., May 16, 2018 – Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). [...]

Archives
Go to Top